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Introduction
Group B streptococcus (GBS) emerged as the leading infec-
tious cause of neonatal morbidity and mortality in the United
States in the 1970s (1–4). Initial case series reported case-
fatality ratios as high as 50%. In the early 1980s, clinical trials
demonstrated that administering antibiotics during labor to
women at risk of transmitting GBS to their newborns could
prevent invasive disease in the first week of life (i.e., early-
onset disease) (5). As a result of the collaborative efforts of
clinicians, researchers, professional organizations, parent
advocacy groups, and the public health community in the
1990s, recommendations for intrapartum prophylaxis to prevent
perinatal GBS disease were issued in 1996 by the American
College of Obstetricians and Gynecologists (ACOG) (6) and
CDC (7), and in 1997 by the American Academy of
Pediatrics (8).
Those guidelines recommended the use of one of two pre-
vention methods, a risk-based approach or a culture-based
screening approach. Providers using the risk-based method
identify candidates for intrapartum chemoprophylaxis accord-
ing to the presence of any of the following intrapartum risk
factors associated with early-onset disease: delivering at <37
weeks’ gestation, having an intrapartum temperature >100.4ºF
(>38.0ºC), or rupture of membranes for >18 hours. The screen-
ing-based method recommends screening of all pregnant
women for vaginal and rectal GBS colonization between 35
and 37 weeks’ gestation. Colonized women are then offered
intrapartum antibiotics at the time of labor. Under both strat-
egies, women with GBS bacteriuria during their current
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Summary
Group B streptococcus (GBS) remains a leading cause of serious neonatal infection despite great progress in perinatal GBS
disease prevention in the 1990s. In 1996, CDC, in collaboration with other agencies, published guidelines for the prevention of
perinatal group B streptococcal disease (CDC. Prevention of perinatal group B streptococcal disease: a public health perspective.
MMWR 1996;45[RR-7]:1–24). Data collected after the issuance of the 1996 guidelines prompted reevaluation of prevention
strategies at a meeting of clinical and public health representatives in November 2001. This report replaces CDC’s 1996 guide-
lines. The recommendations are based on available evidence and expert opinion where sufficient evidence was lacking. Although
many of the recommendations in the 2002 guidelines are the same as those in 1996, they include some key changes:
• Recommendation of universal prenatal screening for vaginal and rectal GBS colonization of all pregnant women at 35–37
weeks’ gestation, based on recent documentation in a large retrospective cohort study of a strong protective effect of this
culture-based screening strategy relative to the risk-based strategy
• Updated prophylaxis regimens for women with penicillin allergy
• Detailed instruction on prenatal specimen collection and expanded methods of GBS culture processing, including instruc-
tions on antimicrobial susceptibility testing
• Recommendation against routine intrapartum antibiotic prophylaxis for GBS-colonized women undergoing planned cesar-
ean deliveries who have not begun labor or had rupture of membranes
• A suggested algorithm for management of patients with threatened preterm delivery
• An updated algorithm for management of newborns exposed to intrapartum antibiotic prophylaxis
Although universal screening for GBS colonization is anticipated to result in further reductions in the burden of GBS disease,
the need to monitor for potential adverse consequences of intrapartum antibiotic use, such as emergence of bacterial antimicrobial
resistance or increased incidence or severity of non-GBS neonatal pathogens, continues, and intrapartum antibiotics are still
viewed as an interim strategy until GBS vaccines achieve licensure.
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pregnancy, or who previously gave birth to an infant with early-
onset GBS disease are candidates for intrapartum antibiotic
prophylaxis.
Before active prevention was initiated, an estimated 7,500
cases of neonatal GBS disease occurred annually (9). Despite
striking declines in disease incidence coinciding with increased
prevention activities in the 1990s, GBS disease remains a lead-
ing infectious cause of morbidity and mortality among new-
borns in the United States (10,11). Moreover, since the release
of the 1996 guidelines, new data are available to evaluate the
effectiveness of the screening approach relative to the risk-based
approach and to resolve some of the clinical challenges of imple-
menting prevention.
In light of these new data, in November 2001, CDC con-
sulted with multiple partners to revise the 1996 guidelines for
the prevention of perinatal group B streptococcal disease,
using an evidence-based approach where possible and scien-
tific opinion when sufficient data were lacking (Table 1). These
updated guidelines replace CDC’s 1996 guidelines. They are
intended for the following groups: providers of prenatal,
obstetric, and pediatric care; supporting microbiology labora-
tories, hospital administrators and managed care organizations;
childbirth educators; public health authorities; and expectant
parents and their advocates.
Differences and similarities between
current and previous guidelines
Following are major differences in the new guidelines:
• Recommendation of universal prenatal culture-based
screening for vaginal and rectal GBS colonization of all
pregnant women at 35–37 weeks’ gestation
• Updated prophylaxis regimens for women with penicillin
allergy
TABLE 1.  Evidence-based rating system used to determine strength of recommendations
Category                                                                           Definition Recommendation
Strength of recommendation
A Strong evidence for efficacy and substantial clinical benefit Strongly recommended
B Strong or moderate evidence for efficacy, but only limited clinical benefit Generally recommended
C Insufficient evidence for efficacy; or efficacy does not outweigh possible adverse consequences Optional
D Moderate evidence against efficacy or for adverse outcome Generally not recommended
E Strong evidence against efficacy or for adverse outcome Never recommended
Quality of  evidence supporting recommendation
I Evidence from at least one well-executed randomized, controlled trial or one rigorously designed
laboratory-based experimental study that has been replicated by an independent investigator
II Evidence from at least one well-designed clinical trial without randomization; cohort or case-controlled
analytic studies (preferably from more than one center); multiple time-series studies; dramatic results
from uncontrolled studies; or some evidence from laboratory experiments
III Evidence from opinions of respected authorities based on clinical or laboratory experience,
descriptive studies, or reports of expert committees
Source: Adapted from CDC, 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency
virus. MMWR 1999; 48(RR-10):1-66.
• Detailed instruction on prenatal specimen collection and
expanded methods of GBS culture processing, including
instructions on susceptibility testing
• Recommendation against routine intrapartum antibiotic
prophylaxis for GBS-colonized women undergoing
planned cesarean deliveries who have not begun labor or
had rupture of membranes
• A suggested algorithm for management of patients with
threatened preterm delivery
• An updated algorithm for management of newborns
exposed to intrapartum antibiotic prophylaxis
Although important changes have been instituted, many
recommendations remain the same:
• Penicillin remains the first-line agent for intrapartum
antibiotic prophylaxis, with ampicillin an acceptable
alternative.
• Women whose culture results are unknown at the time of
delivery should be managed according to the risk-based
approach; the obstetric risk factors remain unchanged (i.e.,
delivery at <37 weeks’ gestation, duration of membrane
rupture >18 hours, or temperature >100.4ºF [>38.0ºC]).
• Women with negative vaginal and rectal GBS screening
cultures within 5 weeks of delivery do not require intra-
partum antimicrobial prophylaxis for GBS even if obstet-
ric risk factors develop (i.e., delivery at <37 weeks’
gestation, duration of membrane rupture >18 hours, or
temperature >100.4ºF [>38.0ºC]).
• Women with GBS bacteriuria in any concentration dur-
ing their current pregnancy or who previously gave birth
to an infant with GBS disease should receive intrapartum
antimicrobial prophylaxis.
• In the absence of GBS urinary tract infection, antimicro-
bial agents should not be used before the intrapartum
period to treat asymptomatic GBS colonization.
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Background
Early Infancy and Pregnancy-Related
Infections
GBS causes severe invasive disease in young infants. The
majority of infections in newborns occur within the first week
of life and are designated early-onset disease. Late-onset infec-
tions occur in infants aged >1 week, with most infections evi-
dent in the first 3 months of life. Young infants with invasive
GBS disease usually present with sepsis or pneumonia, and
less often contract meningitis, osteomyelitis, or septic arthri-
tis. The proportion of infants with meningitis is higher among
those with late-onset infections. When neonatal infections
caused by GBS appeared in the 1970s, as many as 50% of
patients died. During the 1990s, the case-fatality ratio of early-
and late-onset disease was 4% (10) because of advances in
neonatal care.
Intrauterine infection of the fetus results from ascending
spread of GBS from the vagina of a colonized woman who is
typically asymptomatic. Fetal aspiration of infected amniotic
fluid can lead to stillbirth, neonatal pneumonia, or sepsis.
Infants can also become infected with GBS during passage
through the birth canal, although the majority of infants who
are exposed to the organism through this route become colo-
nized on skin or mucous membranes but remain asymptomatic.
In pregnant women, GBS can cause clinical infections, but
most women have no symptoms associated with genital tract
colonization. Urinary tract infections caused by GBS compli-
cate 2%–4% of pregnancies (12,13). During pregnancy or the
postpartum period, women can contract amnionitis,
endometritis, sepsis, or rarely, meningitis caused by GBS
(14–19). Fatalities among women with pregnancy-associated
GBS disease are extremely rare.
GBS Colonization
The gastrointestinal tract serves as the natural reservoir for
GBS and is the likely source of vaginal colonization. Vaginal
colonization is unusual in childhood but becomes more com-
mon in late adolescence (20). Approximately 10% to 30% of
pregnant women are colonized with GBS in the vagina or rec-
tum (21). GBS colonization can be transient, chronic, or
intermittent. Maternal intrapartum GBS colonization is
a major risk factor for early-onset disease in infants, and
vertical transmission of GBS from mother to fetus primarily
occurs after the onset of labor or membrane rupture. How-
ever, colonization early in pregnancy is not predictive of neo-
natal sepsis (22). Culture screening of both the vagina and
rectum for GBS late in gestation during prenatal care can
detect women who are likely to be colonized with GBS at the
time of delivery and are thus at higher risk of perinatal trans-
mission of the organism (23).
Classic epidemiologic studies conducted during the 1980s
revealed that women with prenatal GBS colonization were >25
times more likely than women with negative prenatal cultures
to deliver infants with early-onset GBS disease (24). Researchers
used prenatal cultures as the basis for identifying candidates
for intrapartum antimicrobial chemoprophylaxis; clinical tri-
als identified reductions in vertical transmission of the organ-
ism, as measured by infant colonization (25,26) or by
protection against early-onset disease (5,27). Heavy coloniza-
tion, defined as culture of GBS from direct plating rather than
only from selective broth, is associated with higher risk for
early-onset disease. GBS identified in clean-catch urine speci-
mens is considered a surrogate for heavy maternal coloniza-
tion and also is associated with a higher risk for early-onset
GBS disease (12,13); it has been included among indications
for intrapartum antibiotic prophylaxis.
GBS Culture-Based Screening Methods
Numerous studies have documented that the accuracy of
prenatal screening cultures in identifying intrapartum coloni-
zation status can be enhanced by careful attention to the tim-
ing of cultures, the anatomic sites swabbed, and the precise
microbiologic methods used for culture and detection of
organisms (Box 1). Collection of cultures between 35 and 37
weeks’ gestation is recommended to improve the sensitivity
and specificity of detection of women who remain colonized
at the time of delivery (23,28). Swabbing both the lower
vagina and rectum (i.e., through the anal sphincter) increases
the yield substantially compared with sampling the cervix or
sampling the vagina without also swabbing the rectum (29).
Studies have indicated that when women in the outpatient
clinic setting collect their own screening specimens, with
appropriate instruction, GBS yield is similar to when speci-
mens are collected by a health-care provider (30). Although
swabbing both sites is recommended and use of two swabs
can be justified, both swabs should be placed in a single broth
culture medium because the site of isolation is not important
for clinical management and laboratory costs can thereby be
minimized. Because vaginal and rectal swabs are likely to yield
diverse bacteria, use of selective enrichment broth is recom-
mended (Box 1) to maximize the isolation of GBS and avoid
overgrowth of other organisms. When direct agar plating is
used instead of selective enrichment broth, as many as 50% of
women who are GBS carriers have false-negative culture
results (31).
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Procedure for collecting clinical specimens for culture
of group B streptococcus at 35–37 weeks’ gestation
• Swab the lower vagina (vaginal introitus), followed by the
rectum (i.e., insert swab through the anal sphincter)
using the same swab or two different swabs. Cultures
should be collected in the outpatient setting by the health-
care provider or the patient herself, with appropriate
instruction. Cervical cultures are not recommended and
a speculum should not be used for culture collection.
• Place the swab(s) into a nonnutritive transport medium.
Appropriate transport systems (e.g., Amies or Stuart’s with-
out charcoal) are commercially available. If vaginal and
rectal swabs were collected separately, both swabs can be
placed into the same container of medium. Transport
media will maintain GBS viability for up to 4 days at
room temperature or under refrigeration.
• Specimen labels should clearly identify that specimens are
for group B streptococcal culture. If susceptibility testing
is ordered for penicillin-allergic women (Box 2), speci-
men labels should also identify the patient as penicillin
allergic and should specify that susceptibility testing for
clindamycin and erythromycin should be performed if
GBS is isolated.
Procedure for processing clinical specimens for culture
of group B streptococcus
• Remove swab(s) from transport medium.* Inoculate
swab(s) into a recommended selective broth medium, such
as Todd-Hewitt broth supplemented with either gentami-
cin (8 µg/ml) and nalidixic acid (15 µg/ml), or with colis-
tin (10 µg/ml) and nalidixic acid (15 µg/ml). Examples of
appropriate commercially available options include Trans-
Vag broth supplemented with 5% defibrinated sheep blood
or LIM broth.†
• Incubate inoculated selective broth for 18–24 hours at
35º–37ºC in ambient air or 5% CO2. Subculture the broth
to a sheep blood agar plate (e.g., tryptic soy agar with 5%
defibrinated sheep blood).
BOX 1. Procedures for collecting and processing clinical specimens for group B streptococcal culture and performing susceptibility
testing to clindamycin and erythromycin
• Inspect and identify organisms suggestive of GBS (i.e.,
narrow zone of beta hemolysis, gram-positive cocci, cata-
lase negative). Note that hemolysis may be difficult to
observe, so typical colonies without hemolysis should
also be further tested. If GBS is not identified after
incubation for 18–24 hours, reincubate and inspect at
48 hours to identify suspected organisms.
• Various streptococcus grouping latex agglutination tests
or other tests for GBS antigen detection (e.g., genetic
probe) may be used for specific identification, or the
CAMP test may be employed for presumptive identification.
Procedure for clindamycin and erythromycin disk
susceptibility testing of isolates, when ordered for
penicillin-allergic patients§
• Use a cotton swab to make a suspension from 18–24-hour
growth of the organism in saline or Mueller-Hinton
broth to match a 0.5 McFarland turbidity standard.
• Within 15 minutes of adjusting the turbidity, dip a ster-
ile cotton swab into the adjusted suspension. The swab
should be rotated several times and pressed firmly on
the inside wall of the tube above the fluid level. Use the
swab to inoculate the entire surface of a Mueller-Hinton
sheep blood agar plate. After the plate is dry, use sterile
forceps to place a clindamycin (2 µg) disk onto half of
the plate and an erythromycin (15 µg) disk onto the
other half.
• Incubate at 35ºC in 5% CO2 for 20–24 hours.
• Measure the diameter of the zone of inhibition using a
ruler or calipers. Interpret according to NCCLS guide-
lines for Streptococcus species other than S. pneumoniae
(2002 breakpoints:§ clindamycin: >19 mm = suscep-
tible, 16–18 = intermediate, <15 = resistant; erythro-
mycin: >21 mm = susceptible, 16–20 = intermediate,
<15 = resistant).
* Before inoculation step, some laboratories may choose to roll swab(s) on a single sheep blood agar plate or CNA sheep blood agar plate. This should be done
only in addition to, and not instead of, inoculation into selective broth. The plate should be streaked for isolation, incubated at 35–37ºC in ambient air or 5%
CO2 for 18–24 hours and inspected for organisms suggestive of GBS as described above. If suspected colonies are confirmed as GBS, the broth can be
discarded, thus shortening the time to obtaining culture results.
† Source: Fenton, LJ, Harper MH. Evaluation of colistin and nalidixic acid in Todd-Hewitt broth for selective isolation of group B streptococci. J Clin Microbiol
1979;9:167–9. Although Trans-Vag medium is often available without sheep blood, direct comparison of medium with and without sheep blood has shown
higher yield when blood is added. LIM broth may also benefit from the addition of sheep blood, although the improvement in yield is smaller and sufficient
data are not yet available to support a recommendation.
§ Source: NCCLS. Performance standard for antimicrobial suceptibility testing, M100-S12, Table 2H, Wayne, Pa.: NCCLS, 2002. NCCLS recommends disk
diffusion (M-2) or broth microdilution testing (M-7) for susceptibility testing of GBS. Commercial systems that have been cleared or approved for testing of
streptococci other than S. pneumoniae may also be used. Penicillin susceptibility testing is not routinely recommended for GBS because penicillin-resistant
isolates have not been confirmed to date.
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Additional Risk Factors for Perinatal
GBS Disease
In addition to colonization with GBS, other factors increase
the risk for early-onset disease. These include gestational age
<37 completed weeks, longer duration of membrane rupture,
intraamniotic infection, young maternal age, black race, His-
panic ethnicity, and low maternal levels of anticapsular anti-
body (32–37). In a 1985 report of predictors of early-onset
disease (24), women with gestation <37 weeks, membrane
rupture of >12 hours, or intrapartum temperature >99.5ºF
(37.5ºC) had 6.5 times the risk of having an infant with early-
onset GBS disease compared with women with none of those
factors. Of note, women who had one of these risk factors but
who had negative prenatal screening cultures were at relatively
low risk for early-onset GBS disease (attack rate 0.9 per 1,000
births) compared with women who were colonized prenatally
but had none of the risk factors (attack rate 5.1 per 1,000
births) (24). In a risk-based strategy promoted during the 1990s
as an alternative to prenatal culture-based screening approaches,
prematurity (gestation <37 weeks), intrapartum fever (tem-
perature >100.4ºF or 38ºC), or duration of membrane rup-
ture >18 hours were used as clinical indications for intrapartum
prophylaxis. Previous delivery of an infant with invasive GBS
disease may increase the risk of early-onset disease in subse-
quent deliveries (38,39), and intrapartum treatment of such
women in subsequent pregnancies has been promoted. By
contrast, colonization with GBS in a previous pregnancy is
not considered an indication for intrapartum prophylaxis in
subsequent pregnancies; rather, women require evaluation for
prenatal colonization in each pregnancy. Because colonization
is transient, the predictive value of culture-based screening is
too low to be clinically useful when performed more than
5 weeks before delivery (28); thus, many women with GBS
colonization during one pregnancy will no longer be colo-
nized during subsequent pregnancies.
Impact and Implementation of the
1996 Guidelines
Declines in Perinatal GBS Disease
Incidence in the Era
of Chemoprophylaxis
Before the widespread use of intrapartum antibiotics, the
incidence of invasive neonatal GBS disease ranged from 2 to 3
cases per 1,000 live births (9,40). Active, population-based
surveillance in selected states in 1990, when GBS prevention
was still rarely implemented, projected an incidence of 1.8
cases per 1,000 live births in the United States (early-onset
disease: 1.5/1,000; late-onset: 0.35/1,000) (9).
Coinciding with active prevention efforts in the 1990s, the
incidence of early-onset disease declined by 70% to 0.5 cases
per 1,000 live births in 1999 (Figure 1). Projections from
active surveillance data for 1999 from the Active Bacterial Core
surveillance/Emerging Infections Program Network
(ABCs)(41) estimate that intrapartum antibiotics prevented
nearly 4,500 early-onset cases and 225 deaths that year (10,11).
Other countries that have adopted perinatal GBS disease pre-
vention guidelines similar to the United States have seen com-
parable declines in early-onset disease incidence (42–44).
Recent estimates of early-onset disease incidence in the United
States suggest a slight increase in incidence from 1999 to 2000,
consistent with a plateau in the impact of prevention efforts
(Figure 1).
The incidence of invasive GBS infections among pregnant
women in the United States declined by 21% from 0.29 per
1,000 live births in 1993 to 0.23 in 1998 (10), suggesting that
increased use of intrapartum antibiotics also prevented some
cases of maternal GBS amnionitis and endometritis. In con-
trast, the rate of late-onset disease remained fairly constant
throughout the 1990s (Figure 1). Although intrapartum
chemoprophylaxis for women with heavy GBS colonization
may prevent a portion of late-onset disease, the stable inci-
dence of late-onset disease during a period when use of intra-
partum antibiotics was increasing suggests that this
intervention is not effective against late-onset disease.


































FIGURE 1. Incidence of early- and late-onset invasive group
B streptococcal disease—selected Active Bacterial Core
surveillance areas, 1989–2000, and activities for prevention
of group B streptococcal disease
* ACOG, American College of Obstetricians and Gynecologists; AAP,
American Academy of Pediatrics. Source: Adapted from CDC. Early-
onset group B streptococcal disease, United States, 1998–1999.
MMWR 2000;49:793–6; and Schrag SJ, Zywicki S, Farley MM, et al.
Group B streptococcal disease in the era of intrapartum antibiotic
prophylaxis. N Engl J Med 2000;342:15–20.
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Implementation of Chemoprophylaxis
Strategies After the Release of the
1996 Guidelines
Declines in perinatal GBS disease incidence in the 1990s
suggest that prevention strategies have been implemented
successfully. Several studies have explored directly the chal-
lenges of implementation and extent of compliance with rec-
ommendations. Surveys of prenatal care providers in
Connecticut and Minnesota in 1998 found that over 80%
had a GBS prevention policy (Connecticut, 95%; Minnesota,
85%) (45). In Minnesota, family physicians were less likely to
have a policy than were obstetrician/gynecologists and certi-
fied nurse midwives (45). A national survey of ACOG mem-
bers in 2000 found that 98% of respondents had a GBS
prevention policy; 75% of respondents reported using a ver-
sion of the culture-based screening approach (46). Providers
in all three surveys scored well on questions about their knowl-
edge of the screening and risk-based strategies (45,46).
In hospitals that established or revised policies for GBS pre-
vention shortly after the release of the 1996 guidelines, rates
of early-onset GBS disease declined by 1997 (47). By 1999,
although only 63% of hospitals in a multistate survey of hos-
pitals in the ABCs areas had a formal GBS prevention policy
(48), having a hospital policy was no longer associated with
changes in incidence of GBS disease, likely because a high
proportion of individual practitioners had adopted policies
by this time.
TABLE 2. Institutional-level compliance with 1996 perinatal group B streptococcal disease prevention recommendations
Deliveries with Preterm
Deliveries prolonged ROM* deliveries GBS culture-positive
receiving receiving receiving Women women receiving
Type of population intrapartum intrapartum intrapartum screened intrapartum
sampled (ref.) antibiotics, %* antibiotics, %* antibiotics, %*  overall, % antibiotics, %*
Risk-based strategy evaluated
2 HMO* hospitals, California  (49) –† 88 81 N/A† N/A
University hospital, Florida (50) – 20 in 1992 13 in 1992
72 in 1995 42 in 1995 N/A N/A
Single hospital, Vienna, Austria (51) 11.9 – – N/A N/A
Single hospital, Massachusetts (52) – 81 – N/A N/A
Connecticut (statewide), 1996 (53) 15.2 45 53 N/A N/A
Screening-based strategy evaluated
Community hospital, New York (54) – N/A 76 91 86
University hospital, North Carolina (55) 12.9 for GBS N/A – 98 92
prophylaxis
Single hospital, Sydney, Australia (42) – N/A – 90 –
Single hospital, Vienna, Austria (51) 14.5 N/A 96 98.6 91
University hospital, New Mexico (56) – N/A – 81 72
Single hospital, California (59) 26.3 N/A 91 89.8 94.4
Single hospital, Pennsylvania (57) –- N/A – 92 86
2 HMO hospitals, Washington State (58) – N/A 53 91 74 (automated data)
87 (chart review)
Single hospital, Massachusetts (52) – N/A – N/A 100
Connecticut (statewide), 1996 (53) 15.2 N/A – (36% of Connecticut births) 78
* Given for any reason.
†
ROM, rupture of membranes; HMO, health maintenance organization; –, data not available; N/A, not applicable.
Several studies of single institutions or health maintenance
organizations have evaluated adherence of hospital personnel
to GBS guidelines (Table 2). Among hospitals with a risk-
based policy, intrapartum antibiotics were administered in
40%–80% of preterm deliveries or deliveries with prolonged
rupture of membranes (Table 2) (49–53). Among hospitals
with a culture-based screening policy, close to 90% of deliver-
ing women had documented GBS screening, and close to 90%
of GBS-positive women received intrapartum antibiotics (Table
2) (42,51,54–59).
Correct laboratory processing of culture specimens (Box 1)
plays a critical role in successful implementation of the screen-
ing policy. A survey of clinical laboratories in selected coun-
ties of three states in 1997–1998 found that only a proportion
of laboratories were using the recommended selective broth
media to process GBS cultures (Georgia, 39% of laboratories;
Minnesota, 42%; Connecticut, 62%), suggesting that this may
be an area in need of improvement (31).
Although surveys of practitioners and laboratories and
reports from single hospitals help monitor implementation of
GBS prevention guidelines, a recent CDC-sponsored review
of labor and delivery records in selected counties of eight states
in the ABCs areas in 1998 and 1999 sheds light on actual
provider practices 2 to 3 years after the release of the 1996
guidelines (60). In this population, GBS screening was docu-
mented in 52% of deliveries, although this varied widely, from
24% in selected counties of Oregon to 70% in Maryland.
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Among screened women, 24% were GBS positive, consistent
with carriage rates reported in earlier studies; 89% of GBS-
positive women received intrapartum antibiotics. The median
time of GBS culture collection was at 35.6 weeks’ gestation,
consistent with the recommendation of 35–37 weeks’ gesta-
tion. Among unscreened women, 24% had at least one intra-
partum risk factor; however, only 61% of women with at least
one risk factor received intrapartum antibiotics. Preterm
delivery (<37 weeks’ gestation) was the most common
indication for which intrapartum antibiotics were not admin-
istered. Thus, this multistate record review confirmed trends
in adherence identified in reports from single hospitals (Table 2).
Maximizing Prevention by
Chemoprophylaxis
Effectiveness of the Risk-Based
Approach Versus the Screening
Approach
Despite dramatic declines in GBS incidence in the United
States in the 1990s, GBS remains a leading cause of newborn
morbidity and mortality, resulting in an estimated 1,600 early-
onset cases and 80 deaths annually. Although alternatives to
intrapartum antibiotics such as a vaccine may become avail-
able in the future, intrapartum chemoprophylaxis remains the
most effective available intervention against perinatal GBS
disease. However, debate about the most effective strategy
for identifying candidates for intrapartum chemoprophylaxis
continues.
When the 1996 guidelines were issued, data regarding the
relative effectiveness of the risk-based and screening approaches
were not available. Theoretical predictions based on popula-
tion estimates of the proportion of early-onset GBS cases with-
out obstetric risk factors (approximately 45% in the
preprevention era [61]) suggested that the screening-based
approach would lead to greater declines in disease incidence
than the risk-based approach (61,62). However, because imple-
mentation of the risk-based approach has been viewed as simpler
than the screening-based approach, which requires correct speci-
men collection at the prenatal clinic, appropriate laboratory
processing, and timely reporting of results to delivery staff,
the actual effectiveness of these strategies is unknown. Conse-
quently, since 1996, both approaches have been recommended
as equally acceptable pending further data (6–8).
Although observational data are now available suggesting
that each strategy can lead to reduced incidence of early-onset
GBS disease (49,50,63–65), the strategies have not been
directly compared by clinical trial because of the large sample
size required. A series of single hospital analyses finding ben-
efits of screening over the risk-based approach (51,56,59,66)
were limited by sequential use of the strategies and inability to
control for potential confounders. A recent CDC-sponsored
multistate study provided the first large-scale direct compari-
son of the strategies (60). By incorporating population-based
surveillance for early-onset GBS disease into a sample survey
of a population of over 600,000 live births, this analysis found
that the screening approach was >50% more effective than the
risk-based approach at preventing perinatal GBS disease.
The protective effect of the screening approach was robust
and persisted after controlling for risk factors associated with
early-onset GBS disease (e.g., preterm delivery, prolonged
membrane rupture, young maternal age, black race). The ben-
efit of screening stemmed from two main factors. First, by
identifying GBS-colonized women who did not present with
obstetric risk factors, screening reached more of the popula-
tion at risk than did the risk-based approach. Among the
cohort of screened women, 18% of all deliveries were to moth-
ers who were colonized with GBS but did not have obstetric
risk factors. The efficacy of intrapartum antibiotics in
preventing early-onset GBS disease among infants in this
cohort was close to 90%, suggesting that chemoprophylaxis
of GBS-positive women without obstetric risk factors resulted
in significant prevention of early-onset disease.
Women who were GBS positive in the screening cohort were
also more likely to receive intrapartum antibiotics than were
women with obstetric risk factors in the risk cohort. Although
improvements in implementation of the risk-based approach
would lead to further decline in disease, this would not be as
great as with universal screening (60).
Finally, because the effectiveness of screening in this study
was based on actual implementation of this strategy in clinical
practice in 1998 and 1999, further improvements in screen-
ing implementation (e.g., improvements in specimen collec-
tion and the methods used for processing cultures) are expected
to result in further benefits.
Rationale for a Universal Prenatal
Screening Strategy to Detect GBS
Status
The new availability of category II evidence (Table 1) for a
large protective effect of prenatal GBS screening compared
with the risk-based approach provides the foundation for a
recommendation of universal prenatal GBS screening (Figure 2).
Statewide prevention activities in some ABCs areas further
demonstrate that culture-based screening can be successfully
implemented in a variety of settings and institutions.
For example, a health department-led survey of clinical
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laboratories in Connecticut followed by rapid feedback of sur-
vey results found that the proportion of laboratories in Con-
necticut using the correct media for processing GBS screening
cultures increased from 62% in 1997 to 92% in 1998 (67)
and 100% in 2000. Moreover, coinciding with an active pre-
vention campaign launched by the state health department
that advocated the screening-based approach, the incidence
of early-onset GBS disease in Connecticut declined from 0.6
cases per 1,000 live births in 1996 (68) to 0.2 cases per 1,000
live births in 1999.
 From the standpoint of implementation, universal screen-
ing has two additional benefits over the dual recommenda-
tions of 1996. Communication of the public health messages
associated with a single strategy is simpler than communicat-
ing and educating about multiple strategies. Additionally,
screening has clear indicators that facilitate evaluation of imple-
mentation (e.g., documentation of GBS test, timing of test,
rates of GBS positivity) (58) compared with the risk-based
approach, in which evidence of prevention implementation
cannot be assessed for approximately 75% of deliveries
because they have no intrapartum risk factors.
Cost-effectiveness analyses of the screening- and risk-based
strategies (62,69–73) have indicated that although the initial
costs associated with specimen collection and processing make
the screening strategy more expensive than the risk-based
approach, the overall cost savings due to disease prevention
do not differ importantly between strategies. Additionally,
multistate review of labor and delivery records in 1998 and
1999 suggests that perfect implementation of the screening-
or risk-based strategies will result in a comparable proportion
of deliveries in which women receive intrapartum antibiotic
prophylaxis for GBS (24% for both strategies) (60,74).
Thus, the strategies cannot be distinguished in terms of the
proportion of deliveries that will be exposed to intrapartum
antibiotics.
Adverse Effects and Unintended
Consequences of Chemoprophylaxis
Potential adverse or unintended effects of GBS prevention
efforts that have raised concern include allergic or anaphylac-
tic reactions to agents used for intrapartum antibiotic pro-
phylaxis, emergence of GBS strains resistant to standard
therapies, and increasing incidence of serious neonatal infec-
tions caused by pathogens other than GBS, including antimi-
crobial-resistant strains. Because of the increasing emergence
of bacterial resistance to antimicrobial agents in both nosoco-
mial and community settings, assessment of the impact and
continued effectiveness of interventions based on antimicro-
bial prophylaxis is critical.
FIGURE 2. Indications for intrapartum antibiotic prophylaxis to prevent perinatal GBS disease under a universal prenatal screening
strategy based on combined vaginal and rectal cultures collected at 35–37 weeks’ gestation from all pregnant women
* If onset of labor or rupture of amniotic membranes occurs at <37 weeks’ gestation and there is a significant risk for preterm delivery (as assessed by
the clinician), a suggested algorithm for GBS prophylaxis management is provided (Figure 3).
†
If amnionitis is suspected, broad-spectrum antibiotic therapy that includes an agent known to be active against GBS should replace GBS prophylaxis.
Vaginal and rectal GBS screening cultures at 35–37 weeks’ gestation for pregnant women (unless patient had GBS bacteriuria
during the current pregnancy or a previous infant with invasive GBS disease)
ALL
Intrapartum prophylaxis indicated
• Previous infant with invasive GBS disease
• GBS bacteriuria during current pregnancy
• Positive GBS screening culture during current pregnancy
(unless a planned cesarean delivery, in the absence of labor
or amniotic membrane rupture, is performed)
• Unknown GBS status (culture not done, incomplete,
or results unknown) and any of the following:
• Delivery at <37 weeks’ gestation*
• Amniotic membrane rupture 18 hours>
• Intrapartum temperature 100.4°F ( 38.0°C)> > †
Intrapartum prophylaxis not indicated
• Previous pregnancy with a positive GBS
screening culture (unless a culture was also
positive during the current pregnancy)
• Planned cesarean delivery performed in the
absence of labor or membrane rupture
(regardless of maternal GBS culture status)
• Negative vaginal and rectal GBS screening
culture in late gestation during the current
pregnancy, regardless of intrapartum risk
factors
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Antibiotic Allergies Including
Anaphylaxis
Anaphylaxis associated with GBS chemoprophylaxis occurs
but is sufficiently rare that any morbidity associated with ana-
phylaxis is greatly offset by reductions in the incidence of
maternal and neonatal invasive GBS disease. Anaphylaxis-
related mortality is likely to be a rare event since women
receiving intrapartum antibiotics will be in hospital settings
where rapid intervention is readily available. Estimates of the
rate of anaphylaxis caused by penicillin range from 4/10,000
to 4/100,000 recipients. Additionally, as many as 10% of the
adult population have less severe allergic reactions to penicil-
lin (75). Anaphylaxis associated with GBS prophylaxis was
reported in the early 1990s (76); since the release of the 1996
guidelines, an additional report of a nonfatal case of anaphy-
laxis associated with GBS chemoprophylaxis has been pub-
lished (77). In a CDC multistate sample of over 5,000 live
births, a single, nonfatal anaphylactic reaction was noted
among the 27% of deliveries in which intrapartum antibiotics
were administered (60). In that case, a single dose of penicil-
lin was administered approximately 4 hours before a preterm
cesarean delivery, and an anaphylactic reaction occurred shortly
after the mother received a single dose of a cephalosporin
following umbilical cord clamping.
Resistance in GBS
GBS isolates with confirmed resistance to penicillin or ampi-
cillin have not been observed to date (78–83). Penicillin
remains the agent of choice for intrapartum antibiotic pro-
phylaxis. Ampicillin is an acceptable alternative, but penicil-
lin is preferred because it has a narrower spectrum of
antimicrobial activity and may be less likely to select for resis-
tant organisms. The efficacy of both penicillin (27) and ampi-
cillin (5) as intrapartum agents for the prevention of early-onset
neonatal GBS disease has been demonstrated in clinical trials.
Although the intramuscular route of administration for peni-
cillin has been evaluated (25), intravenous administration is
the only route of administration recommended for intra-
partum chemoprophylaxis to prevent perinatal GBS disease,
regardless of the antimicrobial agent used, because of the higher
intraamniotic concentrations achieved with this method.
In contrast, the proportions of GBS isolates with in vitro
resistance to clindamycin and erythromycin have increased
since 1996. The prevalence of resistance among invasive GBS
isolates in the United States and Canada ranged from 7% to
25% for erythromycin and from 3% to 15% for clindamycin
in reports published between 1998 and 2001(79–81,84).
Resistance to erythromycin is frequently but not always asso-
ciated with clindamycin resistance. Resistance of GBS isolates
to cefoxitin, a second-generation cephalosporin sometimes used
as a component of broad-spectrum coverage for
chorioamnionitis, has also been reported (85); cefoxitin resis-
tance has similarly been observed among invasive GBS iso-
lates collected from 1996 to 2000 as part of CDC’s active
surveillance. Whether in vitro resistance of GBS has direct
clinical implications remains unclear (86). Despite emerging
resistance to some drug classes, minimum inhibitory concen-
trations of cefazolin, a first-generation cephalosporin avail-
able in an intravenous formulation, were low (<0.5 µg/ml)
among a sample of invasive U.S. isolates from 1996 to 2000
(87), suggesting that GBS isolates are currently susceptible to
this agent. Although NCCLS guidelines do not specify sus-
ceptibility breakpoints for cefazolin, they recommend that all
isolates susceptible to penicillin be considered susceptible to
cefazolin (88).
In light of the increasing prevalence of resistance to
clindamycin, erythromycin, or both, recommended strategies
for providing intrapartum antibiotic prophylaxis to penicillin-
allergic women are updated (Box 2). Because the efficacy of
recommended alternatives to penicillin or ampicillin has not
been measured in controlled trials, and because some of the
recommended alternatives have a broad spectrum of activity
and may be more complicated and costly to administer, verifi-
cation of a reported history of penicillin allergy is important.
Patients with reported penicillin allergy should then be
assessed to determine their risk for anaphylaxis. Persons at high
risk for anaphylaxis are those who have had immediate hyper-
sensitivity reactions to penicillin (e.g., anaphylaxis,
angioedema, or urticaria) or who have a history of asthma or
other conditions that would make anaphylaxis more danger-
ous (89,90). An estimated 10% of persons with penicillin
allergy also have immediate hypersensitivity reactions to cepha-
losporins (90). Among penicillin-allergic women not at high
risk for anaphylaxis, cefazolin, because of its narrow spectrum
of activity and ability to achieve high intraamniotic concen-
trations, is the agent of choice for intrapartum chemoprophylaxis.
For penicillin-allergic women at high risk for anaphylaxis,
testing of GBS isolates from prenatal screening for suscepti-
bility to clindamycin and erythromycin is recommended if
feasible (Box 1). One of these agents should be employed for
intrapartum GBS prophylaxis if the screening isolate is
susceptible to both agents.
Vancomycin should be reserved for penicillin-allergic women
at high risk for beta-lactam anaphylaxis when clindamycin or
erythromycin are not options because of in vitro resistance or
unknown susceptibility of a prenatal isolate. Vancomycin use
is generally restricted because of emerging vancomycin resis-
tance among some gram-positive organisms (e.g., vancomycin-
resistant enterococcus and vancomycin-resistant Staphylococcus
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aureus). An estimated 13.8 million hospitalized patients
received vancomycin therapy in 1998 (91). If penicillin
allergy occurs in approximately 10% of adults, and 25% of
parturients are colonized with GBS prenatally, approximately
100,000 of the 4 million annual deliveries would require pro-
phylaxis with vancomycin in the absence of clindamycin and
erythromycin susceptibility testing of GBS prenatal isolates.
This represents a 7% increase in the number of patients
exposed to vancomycin. The total grams of vancomycin used
annually would increase by less than 1% if all penicillin-
allergic colonized women received vancomycin prophylaxis.
Increased Incidence or Resistance in
Non-GBS Pathogens
Decreases in the incidence of early-onset GBS sepsis have
not usually been accompanied by increases in incidence of
early-onset sepsis caused by other pathogens, including those
that are antibiotic resistant. Most studies, including popula-
tion-based multicenter studies, have found stable (59,92,93)
or decreasing (43) rates of non-GBS early-onset sepsis during
a period of increasing use of intrapartum antibiotic prophy-
laxis for GBS (Table 3). This is true both for overall non-GBS
sepsis and for neonatal sepsis caused by Escherichia coli, the
second leading bacterial cause of neonatal sepsis after GBS
(93,94). Some single hospital studies have found increased
rates or case counts of neonatal sepsis caused by E. coli, gram-
negative organisms in general, or ampicillin-resistant patho-
gens (64,94,95), but these increases appear to be limited to
preterm or low-birth-weight infants. An increasing propor-
tion of E. coli neonatal sepsis cases caused by ampicillin-
resistant organisms was observed in two studies (92,94), but
again was limited to preterm or low-birth-weight infants. Fur-
thermore, the proportion of community-acquired E. coli
infections that are ampicillin resistant has been increasing (96),
suggesting that trends in antimicrobial resistance should not
be attributed to GBS prophylaxis.
An association between intrapartum antibiotic exposure and
ampicillin resistance in cases of E. coli or other non-GBS early-
onset sepsis has been observed in several studies (36,94,95,
97,98). These reports established that infections caused by
antibiotic-resistant organisms were more frequently preceded
by antibiotic use than were infections caused by susceptible
organisms, and that more doses or longer duration of anti-
biotics before delivery increased the chance that a neonatal
infection, if it occurred, would be caused by an antibiotic-
resistant organism. These studies, however, were not designed
to assess whether intrapartum antibiotic use increased the rate
of antibiotic-resistant infections. Moreover, findings from these
studies are consistent with intrapartum antibiotics inducing
BOX 2. Recommended regimens for intrapartum antimicrobial
prophylaxis for perinatal GBS disease prevention*
Recommended Penicillin G, 5 million units IV
initial dose, then 2.5 million
units IV every 4 hours until
delivery
Alternative Ampicillin, 2 g IV initial dose,
then 1 g IV every 4 hours until
delivery
If penicillin allergic†
Patients not at high Cefazolin, 2 g IV initial dose,
risk for anaphylaxis then 1 g IV every 8 hours until
delivery
Patients at high risk
for anaphylaxis§
GBS susceptible Clindamycin, 900 mg IV
to clindamycin every 8 hours until delivery
and erythromycin¶
                    OR
Erythromycin, 500 mg IV every
6 hours until delivery
GBS resistant to Vancomycin,** 1 g IV every




* Broader-spectrum agents, including an agent active against GBS, may
be necessary for treatment of chorioamnionitis.
† History of penicillin allergy should be assessed to determine whether a
high risk for anaphylaxis is present. Penicillin-allergic patients at high
risk for anaphylaxis are those who have experienced immediate hyper-
sensitivity to penicillin including a history of penicillin-related anaphy-
laxis; other high-risk patients are those with asthma or other diseases
that would make anaphylaxis more dangerous or difficult to treat, such
as persons being treated with beta-adrenergic–blocking agents.
§ If laboratory facilities are adequate, clindamycin and erythromycin sus-
ceptibility testing (Box 1) should be performed on prenatal GBS isolates
from penicillin-allergic women at high risk for anaphylaxis.
¶ Resistance to erythromycin is often but not always associated with
clindamycin resistance. If a strain is resistant to erythromycin but
appears susceptible to clindamycin, it may still have inducible resistance
to clindamycin.
** Cefazolin is preferred over vancomycin for women with a history of
penicillin allergy other than immediate hypersensitivity reactions, and
pharmacologic data suggest it achieves effective intraamniotic concen-
trations. Vancomycin should be reserved for penicillin-allergic women at
high risk for anaphylaxis.
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resistance among initially susceptible organisms, but also with
intrapartum antibiotics preventing antibiotic-susceptible
infections and having no impact on antibiotic-resistant infec-
tions, resulting in a net decrease in the total rate of infection.
The reported increases in antibiotic-resistant early-onset
infections in a few studies are not of sufficient magnitude to
outweigh the benefits of intrapartum antibiotic prophylaxis
to prevent perinatal GBS disease. However, to assure early
detection of increases in the rate of disease or deaths caused
by organisms other than GBS, continued surveillance of
neonatal sepsis caused by organisms other than GBS is needed.
Clinical Challenges
GBS Bacteriuria During Pregnancy
The presence of GBS bacteriuria in any concentration in a
pregnant woman is a marker for heavy genital tract coloniza-
tion. Therefore, women with any quantity of GBS bacteriuria
during pregnancy should receive intrapartum chemoprophylaxis.
Vaginal and rectal screening at 35–37 weeks is not necessary
for these women. GBS can cause both symptomatic and
asymptomatic urinary tract infections, which should be diag-
nosed and treated according to current standards of care for
urinary tract infections in pregnancy. Women with GBS uri-
nary tract infections during pregnancy should receive
appropriate treatment at the time of diagnosis as well as intra-
partum GBS prophylaxis. Laboratory personnel should report
any presence of GBS bacteriuria in specimens obtained from
pregnant women. For this to occur, labeling of urine speci-
mens to indicate that they were obtained from a pregnant
woman is imperative.
Planned Cesarean Delivery
Because GBS can cross intact amniotic membranes, a cesar-
ean delivery does not prevent mother-to-child transmission of
GBS. Moreover, because cesarean delivery itself is associated
with health risks for mother and newborn, GBS colonization of
TABLE 3. Trends in neonatal sepsis incidence in the era of perinatal GBS disease prevention
Total Cause of early-
Study site births onset sepsis Number of cases (rate per 1,000 live births) p-value
Illinois 61,498 1982–1987 1988–1993
(1 hospital) (94) E. coli 12  (0.37) 18 (0.62) NS*
E. coli (among low-
birth-weight† infants) 2 (0.64) 8 (2.63) 0.05
California 29,897    1991  1992   1993    1994    1995    1996
(1 hospital) (95) GBS 5 (0.93) 3 (0.6) 2 (0.41) 2 (0.41) 2 (0.42) 1 (0.21) NS
Non-GBS 3 (0.56) 4 (0.8) 3 (0.61) 4 (0.81) 5 (1.04) 8 (1.65) NS
E. coli 0 (0) 1 (0.2) 1 (0.2) 2 (0.41) 2 (0.42) 5 (1.03) 0.001
Illinois 20,981 1992–1996 1997
(1 hospital) (64) GBS 30 (1.7) 0 (0) 0.02
All causes –§ (2.7) – (2.1) NS
All gram negative 5 (0.29) 5 (1.3) 0.02
Connecticut 140,923 1996 1997 1998 1999
(19 hospitals) (92) GBS 20 (0.56) 17 (0.49) 20 (0.56) 8 (0.23) 0.01
Non-GBS 24 (0.68) 23 (0.66) 24 (0.68) 23 (0.65) NS
E. coli 5 (0.14) 12 (0.35) 14 (0.39) 8 (0.23) NS
Australia 172,947 1991–1993 1993–1995 1995–1997
(multiple hospitals) (43) GBS 33 (1.4) 68 (0.9) 27 (0.4) <0.0001
Non-GBS 30 (1.3) 63 (0.8) 29 (0.4) <0.0001
California 29,403 1992–1993 1994–1996 1997–1998 1999–2000
(1 hospital) (59) GBS 8 (1.2) 15 (1.1) 0 (0) 2 (0.2) 0.001
Non-GBS 11 (1.6) 14 (1.1) 7 (0.8) 6 (0.6) NS
Ohio 41,738 1986–1991 1992–1997
(1 hospital) (93) GBS 24 (1.1) 11 (0.54) 0.04
Non-GBS 28 (1.3) 29 (1.4) NS
* NS = not statistically significant.
†
Low birth weight defined as 1,501–2,500 g.
§
Data not available.
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the mother is not an indication for cesarean delivery, and
cesarean delivery should not be used as an alternative to intra-
partum antibiotic prophylaxis for GBS prevention.
However, although a risk does exist for transmission of GBS
from a colonized mother to her infant during a planned cesar-
ean delivery performed before onset of labor in a woman with
intact amniotic membranes, it is extremely low, based on a
retrospective study at a single hospital (99) and a review of
CDC active, population-based surveillance data from the
1990s. Thus, in this specific circumstance, in which the risk
for disease is extremely low, the individual risks to a mother
and her infant from receiving intrapartum antibiotic prophy-
laxis may balance or outweigh the benefits. Intrapartum anti-
biotic prophylaxis to prevent perinatal GBS disease is, therefore,
not recommended as a routine practice for women undergo-
ing planned cesarean deliveries in the absence of labor or am-
niotic membrane rupture, regardless of the GBS colonization
status of the mother. Patients expected to undergo planned
cesarean deliveries should nonetheless still undergo routine
vaginal and rectal screening for GBS at 35–37 weeks because
onset of labor or rupture of membranes may occur before the
planned cesarean delivery. In rare situations in which patients
or providers opt for intrapartum prophylaxis before planned
cesarean deliveries, administration of antibiotics at the time
of incision rather than at least 4 hours
before delivery may be reasonable (100).
Threatened Preterm
Delivery
Because preterm (at <37 weeks’ gesta-
tion) delivery is an important risk factor
for early-onset GBS disease, and because
timing of delivery can be difficult to
assess, management of intrapartum pro-
phylaxis for women with threatened
preterm delivery can be challenging.
Assessing the need for intrapartum pro-
phylaxis for these women can also be
difficult because GBS screening is recom-
mended at 35 to 37 weeks’ gestation, and
culture results are not always available
when labor or rupture of membranes
occur preterm.
A suggested approach to GBS chemo-
prophylaxis in the context of threatened
preterm delivery is outlined (Figure 3).
Because insufficient data are available to
suggest a single course of management,
other management strategies developed
by individual physicians or institutions may be appropriate
alternatives. The algorithm suggests that if GBS screening cul-
ture results from the current pregnancy are not available and if
onset of labor or rupture of membranes occurs before 37 weeks’
gestation with a substantial risk for preterm delivery (as
assessed by the woman’s health-care provider), intrapartum
antibiotic prophylaxis for GBS should be provided pending
culture results. For women not yet screened for GBS, a vagi-
nal and rectal specimen for GBS culture should be obtained if
time permits. If a negative culture result within the previous
4 weeks is on record, or if the clinician determines that labor
can be successfully arrested and preterm delivery averted,
antibiotics for GBS prophylaxis should not be initiated.
Because recent clinical trials suggest that antibiotics adminis-
tered during pregnancy may be associated with adverse neo-
natal outcomes, such as necrotizing enterocolitis or increased
need for supplementary oxygen, without evident benefit for
preterm labor or preterm premature rupture of membranes
(101,102), antibiotics should be reserved for instances in which
a significant risk for preterm delivery is present.
No data are available on which to recommend a specific
duration of antibiotic administration for GBS-positive women
with threatened preterm delivery when delivery is successfully
postponed. Management strategies based on scientific opinion
FIGURE 3. Sample algorithm for GBS prophylaxis for women with threatened preterm
delivery.  This algorithm is not an exclusive course of management. Variations that
incorporate individual circumstances or institutional preferences may be appropriate.
Onset of labor or rupture of membranes at <37 weeks’ gestation

















* Penicillin should be continued for a total of at least 48 hours, unless delivery occurs sooner. At the
physician’s discretion, antibiotic prophylaxis may be continued beyond 48 hours in a GBS culture-
positive woman if delivery has not yet occurred. For women who are GBS culture positive, antibiotic
prophylaxis should be reinitiated when labor likely to proceed to delivery occurs or recurs.
†
If delivery has not occurred within 4 weeks, a vaginal and rectal GBS screening culture should be
repeated and the patient should be managed as described, based on the result of the repeat culture.
§
Intrapartum antibiotic prophylaxis.
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have been proposed (100); without further data, the manage-
ment approach is left to the discretion of the individual pro-
vider. Regardless of management strategy chosen, these women
should also receive intrapartum antibiotic chemoprophylaxis
for GBS when labor likely to proceed to delivery occurs or
recurs.
Previous data (28) suggest that the accuracy of GBS screen-
ing cultures in predicting colonization status at delivery is great-
est if the cultures are collected within 5 weeks of delivery.
Therefore, if a woman is screened early for GBS because of
threatened preterm delivery but does not deliver within
4 weeks, she should be screened again for GBS colonization




Questions have arisen regarding whether certain obstetric
procedures, such as digital vaginal examinations, intrauterine
fetal monitoring, and membrane stripping or sweeping to has-
ten the onset of labor, should be performed on GBS-
colonized women. Asymptomatic GBS colonization is not an
indication to perform any of these procedures. When such
procedures are indicated for other reasons, evidence is cur-
rently not sufficient to recommend that particular procedures
should be avoided because of increased risk of peripartum or
perinatal infection. Although some obstetric procedures (fre-
quent vaginal examinations after onset of labor or membrane
rupture [17,36,103–105], intrauterine fetal monitoring
[104,106,107], and mechanical cervical ripening devices [108])
have been significantly associated with peripartum or perina-
tal infectious outcomes, most studies to date have been lim-
ited by an inability to randomly allocate women to treatment
groups and have yielded conflicting results. Moreover, because
many studies were performed before GBS prevention was
widely implemented, GBS colonization status was often not
known and intrapartum chemoprophylaxis was less common.
A meta-analysis of available studies examining the use of mem-
brane stripping among women of undetermined GBS coloni-
zation status (109) found no significant increases in overall
peripartum or perinatal infection rates among women who
underwent this procedure and their infants compared with
those who did not.
Management of Newborns Exposed
to Intrapartum Prophylaxis
On the basis of information available since the publication
of the 1996 guidelines, a modified approach for empiric
management of newborns born to women who receive
intrapartum antibiotics to prevent early-onset GBS disease or
to treat suspected chorioamnionitis is provided (Figure 4).
Variations in the algorithm that incorporate individual cir-
cumstances or institutional preferences may be appropriate.
The modified approach contains the following changes:
• If a woman receives intrapartum antibiotics for treatment
of suspected chorioamnionitis, her newborn should have
a full diagnostic evaluation and empiric therapy pending
* If no maternal intrapartum prophylaxis for GBS was administered
despite an indication being present, data are insufficient on which to
recommend a single management strategy.
† Includes complete blood cell count and differential, blood culture, and
chest radiograph if respiratory abnormalities are present. When signs of
sepsis are present, a lumbar puncture, if feasible, should be performed.
§ Duration of therapy varies depending on results of blood culture, cere-
brospinal fluid findings, if obtained, and the clinical course of the infant.
If laboratory results and clinical course do not indicate bacterial infec-
tion, duration may be as short as 48 hours.
¶ CBC with differential and blood culture.
** Applies only to penicillin, ampicillin, or cefazolin and assumes recom-
mended dosing regimens (Box 2)
†† A healthy-appearing infant who was >38 weeks’ gestation at delivery
and whose mother received >4 hours of intrapartum prophylaxis before
delivery may be discharged home after 24 hours if other discharge crite-
ria have been met and a person able to comply fully with instructions for
home observation will be present. If any one of these conditions is not
met, the infant should be observed in the hospital for at least 48 hours
and until criteria for discharge are achieved.
FIGURE 4. Sample algorithm for management of a newborn
whose mother received intrapartum antimicrobial agents for
prevention of early-onset group B streptococcal disease* or
suspected chorioamnionitis.  This algorithm is not an
exclusive course of management. Variations that incorporate











Observe 48 hours> ††
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culture results, regardless of clinical condition at birth,
duration of maternal antibiotic therapy before delivery,
or gestational age at delivery (110). Empiric therapy for
the infant should include antimicrobial agents active
against GBS as well as other organisms that might cause
neonatal sepsis (e.g., ampicillin and gentamicin).
• When clinical signs in the infant suggest sepsis, a full
diagnostic evaluation should include a lumbar puncture,
if feasible. Blood cultures can be sterile in as many as 15%
of newborns with meningitis (111–113), and the clinical
management of an infant with abnormal cerebrospinal
fluid (CSF) findings differs from that of an infant with
normal CSF. If a lumbar puncture has been deferred for a
neonate receiving empiric antibiotic therapy, and the
therapy is continued beyond 48 hours because of clinical
instability, CSF should be obtained for cell count,
glucose, protein, and culture.
• In addition to penicillin or ampicillin, initiation of intra-
partum antibiotic prophylaxis with cefazolin at least
4 hours before delivery can be considered adequate, based
on achievable amniotic fluid concentrations of cefazolin
(114). Although other agents may be substituted for
penicillin if the woman has a history of penicillin allergy
(Box 2), the effectiveness of these agents in preventing
early-onset GBS disease has not been studied and no data
are available to suggest the durations before delivery of
these regimens that can be considered adequate.
• Based on the demonstrated effectiveness of intrapartum
antibiotic prophylaxis at preventing early-onset GBS dis-
ease (65) and data indicating that clinical onset occurs
within the first 24 hours of life in over 90% of infants
who contract early-onset GBS disease (115), hospital dis-
charge as early as 24 hours after delivery may be reason-
able under certain circumstances. Specifically, a
healthy-appearing infant who is >38 weeks’ gestation at
delivery and whose mother received >4 hours of intrapar-
tum antibiotic prophylaxis before delivery may be dis-
charged home as early as 24 hours after delivery, assuming
that other discharge criteria have been met and that a per-
son able to comply fully with instructions for home
observation will be present. A key component of follow-
ing instructions is the ability of the person observing to
communicate with health-care providers by telephone and
to transport the child promptly to an appropriate health-
care facility if clinical signs of sepsis develop. If these con-
ditions are not met, the infant should remain in the
hospital for at least 48 hours of observation and until cri-
teria for discharge are achieved.
Investigations since 1996 lend additional support to several
components of the algorithm. A retrospective study of over
250,000 live births (115) found that administration of intra-
partum antibiotic prophylaxis did not change the clinical
spectrum of neonatal illness or delay the onset of clinical signs
among infants who contracted GBS disease despite prophy-
laxis. Thus, the algorithm targets infants born to mothers with
suspected chorioamnionitis and infants with signs of sepsis
for full diagnostic evaluation and empiric therapy. Also, new
evidence indicates that 4 or more hours of intrapartum ampi-
cillin or penicillin administered according to recommended
dosing intervals (Box 2) significantly reduces vertical trans-
mission of GBS (116) and risk of early-onset GBS disease (65).
Thus, although the American Academy of Pediatrics 1997
guidelines suggested 2 or more doses as a threshold for pro-
phylaxis adequacy for infants >35 weeks’ gestation (8), the
revised algorithm continues to use >4 hours, administered
according to recommended dosing intervals, as the benchmark
for optimal prevention of early-onset GBS disease. Moreover,
a review of pregnancies at a West Coast health maintenance
organization using the GBS culture-based screening strategy
found that among women who received intrapartum antibi-
otic prophylaxis, 50% received prophylaxis at least 4 hours
before delivery, whereas only 14% received at least 2 doses of
intrapartum antibiotics (58); this indicates that duration of
prophylaxis is a more practical target than number of doses, in
addition to being associated with efficacy.
One objective of developing an algorithm for management
of newborns was to minimize unnecessary evaluation and
antimicrobial treatment of infants whose mothers received
intrapartum prophylaxis. Although early provider surveys
indicated that pediatricians and neonatologists were more likely
to conduct diagnostic evaluations and initiate empiric anti-
biotics for an infant whose mother received intrapartum anti-
biotic prophylaxis (117–119), more recent data indicate that
implementation of GBS prevention strategies has not resulted
in increased use of health services for neonates (120), and in
some circumstances, when GBS prophylaxis increased a
decrease occurred in the proportion of neonates who received
laboratory evaluations (58).
 Intrapartum antibiotic prophylaxis is the method of choice
for preventing neonatal early-onset GBS disease. In the event
that intrapartum antibiotics are not given despite an indica-
tion (e.g., delivery occurred precipitously before antibiotics
could be administered to a GBS-positive woman), sufficient
data are not available on which to recommend a single man-
agement strategy for the newborn. Some centers provide
intramuscular penicillin to asymptomatic infants within 1 hour
of birth, based on results of observational studies showing
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declines in early-onset GBS disease coincident with a policy
of universal administration of intramuscular penicillin to all
newborns (121).
Future Prevention Technology
Rapid Tests to Detect GBS Colonization
Status
Rapid tests for detection of GBS colonization at the time of
onset of labor or rupture of amniotic membranes might obvi-
ate the need for prenatal culture-based screening if their sensi-
tivity and specificity are comparable to culture in selective broth
media and they yield results rapidly enough to permit admin-
istration of adequate intrapartum antibiotic prophylaxis to
women detected as carriers. Currently available rapid tests
detect GBS antigen from swab specimens. These tests are
insufficiently sensitive to detect light colonization, and there-
fore are not adequate to replace culture-based prenatal screen-
ing (122,123) or to use in place of the risk-based approach
when culture results are unknown at the time of labor. An
adequate rapid intrapartum test must be as sensitive as culture
(minimally 85% compared with culture of vaginal and rectal
swabs inoculated into selective broth media), rapid so that
results are available to clinicians in time for antibiotics to be
given before delivery, and convenient for integration into rou-
tine laboratory use. Even a highly sensitive rapid detection
test would not be adequate if results were not available to cli-
nicians 24 hours a day, 7 days a week. Alternatives to cultur-
ing vaginal and rectal swab specimens at 35–37 weeks’ gestation
using recommended procedures should be validated to show
sensitivity similar to recommended culture methods.
A rapid intrapartum test possessing the attributes described
above offers the advantage of ascertaining GBS colonization
status before delivery among women who have had no pre-
natal care. Although such tests might initially be introduced
selectively in certain facilities with sufficient demand and
capability, a general recommendation for their use would
require the capacity for effective implementation in a wide
range of hospital settings. Drawbacks of rapid tests include
delays in administration of intrapartum antibiotic prophylaxis
while test results are pending and lack of an isolate for suscep-
tibility testing, which is of particular concern for penicillin-
allergic women. Additionally, until rapid tests are universally
used, missed opportunities for GBS screening may occur
among women who receive prenatal care at institutions rely-
ing on intrapartum rapid tests but who deliver at institutions
where such tests are not yet available.
In a study of 112 pregnant women at an academic hospital
in Quebec, a new, not yet commercially available fluorogenic
polymerase chain reaction assay was 97% sensitive and 100%
specific when compared with vaginal and rectal cultures
collected at admission for delivery. Test results in this study
were available within 45 minutes of specimen collection (124).
Further studies are needed to determine whether this type of
test can be adapted for use outside the research setting. If
appropriate techniques for rapid detection of GBS become
commercially available, they may be integrated into the
currently recommended screening strategy.
Vaccines To Prevent GBS Disease
Improved use of intrapartum antimicrobial prophylaxis has
resulted in a substantial reduction in early-onset GBS disease,
but it is unlikely to prevent most late-onset neonatal infec-
tions, GBS-related stillbirths, or prematurity, and does not
address GBS disease in nonpregnant adults. Immunization of
women during or before pregnancy could prevent peripartum
maternal disease and protect infants from perinatally acquired
infection by transplacental transfer of protective IgG antibod-
ies (125,126). This would eliminate the need for prenatal GBS
screening and intrapartum antimicrobial prophylaxis, along
with associated costs and concerns regarding the potential
adverse effects of intrapartum antibiotic use discussed previ-
ously.
Serotype-specific antibodies to GBS capsular polysaccharide,
although rare in populations of unvaccinated women, have
been shown to protect against disease (32,127). Phase 1 and 2
clinical trials among healthy, nonpregnant adults of monova-
lent protein-conjugate vaccines containing capsular polysac-
charide antigens of GBS disease-associated serotypes have
shown these vaccines to be well tolerated and immunogenic
(128–130). One challenge of demonstrating vaccine
efficacy in preventing early-onset GBS disease is that the sample
size required for clinical trials may be prohibitively large. Iden-
tification of surrogate immunologic measures of clinical effi-
cacy may thus be important (131,132). Surrogate information
on clinical vaccine efficacy may also be gained by measuring
the impact of multivalent conjugate vaccines on vaginal GBS
colonization (132,133).
Anticipated difficulties in making vaccine available to preg-
nant women have resulted in consideration of other target
populations for vaccine administration, including adolescent
girls (134), women of childbearing age, and infants (135).
The duration of protection that could be afforded by vaccina-
tion is unknown; one or more booster doses might be required,
potentially complicating vaccine delivery. Shifts in the GBS
serotypes causing disease have provided an additional
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challenge to vaccine development (133) and may necessitate
modification of vaccine serotype composition over time.
Research Priorities and Tools To Aid
Prevention
Technological advances that aid the implementation of a
universal screening strategy will further prevention efforts. In
addition to development of reliable rapid tests that can be
performed in a wide range of labor and delivery settings, meth-
ods of simplifying prenatal culture procedures, e.g., the devel-
opment of media with a reliable color indicator to signal
presence of GBS, might improve accuracy of prenatal culture
results and facilitate prenatal culture processing at clinical labo-
ratories with limited technical capacity. Media that have been
developed for this purpose, such as Granada (136,137) or GBS
medium (138), should be further evaluated to determine if
sensitivity and specificity are comparable to recommended
methods, which consist of culture in selective broth media
followed by GBS-specific identification.
Although universal prenatal GBS culture-based screening is
likely to result in substantial further declines in the incidence
of early-onset disease, intrapartum chemoprophylaxis is not a
permanent or comprehensive strategy for GBS disease preven-
tion. Because vaccines under development hold promise to
prevent a larger portion of the burden of GBS disease with a
simpler and sustainable intervention, further work on GBS
vaccine development and support of phase 3 clinical trials are
warranted (139).
Until a safe, effective, and economical vaccine achieves
licensure, it will be important to continue to monitor for
potential adverse effects of chemoprophylaxis, with an
emphasis on tracking key sentinel events signaling a need for
revision of the guidelines. Such sentinel events include the
emergence of penicillin resistance among GBS, which to date
has not been detected, and an increase in the incidence of
disease or deaths due to neonatal pathogens other than GBS
that offsets the burden of early-onset disease prevented by
chemoprophylaxis. Monitoring for the latter will require long-
term surveillance of a large population of term and preterm
births (140).
Because GBS carriage is common among delivering women
in the United States, continued surveillance for GBS disease
and evaluation of prevention implementation remains impor-
tant to minimize missed opportunities for prevention. States
are encouraged to monitor incidence of GBS disease, to pro-
mote activities that enhance perinatal GBS disease prevention
and education, and to assess progress toward national
objectives for disease reduction, such as Healthy People 2010,
which sets a target of reducing the incidence of early-onset
GBS disease in all racial and ethnic groups to 0.5 cases per
1,000 live births (141). Practical tools to assist with monitor-
ing for missed opportunities for perinatal GBS prevention
within hospitals have been published (142); additional pre-
vention information and tools for providers, patients and clini-





The following updated recommendations for the preven-
tion of GBS disease are based on critical appraisal of multistate
population-based observational data and several studies from
individual institutions that have been completed since publi-
cation of previous CDC (7), ACOG (6), and AAP (8) recom-
mendations. They replace previous recommendations from
CDC. The strength (indicated by a letter) and quality (indi-
cated by a roman numeral) of evidence supporting each rec-
ommendation are shown in parentheses, according to the
evidence-based rating system outlined in Table 1.
Obstetric-care practitioners, in conjunction with support-
ing laboratories and labor and delivery facilities, should adopt
the following strategy for the prevention of perinatal GBS dis-
ease based on prenatal screening for GBS colonization. The
risk-based approach is no longer an acceptable alternative
except for circumstances in which screening results are not
available before delivery (AII).
• All pregnant women should be screened at 35–37 weeks’
gestation for vaginal and rectal GBS colonization
(Figure 2) (AII). At the time of labor or rupture of mem-
branes, intrapartum chemoprophylaxis should be given
to all pregnant women identified as GBS carriers (AII).
Colonization during a previous pregnancy is not an indica-
tion for intrapartum prophylaxis in subsequent deliveries.
Screening to detect GBS colonization in each pregnancy
will determine the need for prophylaxis in that pregnancy.
• Women with GBS isolated from the urine in any concen-
tration (e.g., 103) during their current pregnancy should
receive intrapartum chemoprophylaxis because such
women usually are heavily colonized with GBS and are at
increased risk of delivering an infant with early-onset GBS
disease (BII). Labels on urine specimens from prenatal
patients should clearly state the patient’s pregnancy status
to assist laboratory processing and reporting of results.
Prenatal culture-based screening at 35–37 weeks’ gesta-
tion is not necessary for women with GBS bacteriuria.
Women with symptomatic or asymptomatic GBS urinary
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tract infection detected during pregnancy should be treated
according to current standards of care for urinary tract
infection during pregnancy.
• Women who have previously given birth to an infant with
invasive GBS disease should receive intrapartum chemo-
prophylaxis; prenatal culture-based screening is not
necessary for these women (BII).
• If the result of GBS culture is not known at the onset of
labor, intrapartum chemoprophylaxis should be adminis-
tered to women with any of the following risk factors:
gestation <37 weeks, duration of membrane rupture >18
hours, or a temperature of >100.4º F (>38.0ºC) (AII).
Women with known negative results from vaginal and
rectal GBS screening cultures within 5 weeks of delivery
do not require prophylaxis to prevent GBS disease even if
any of the intrapartum risk factors develop.
• Women with threatened preterm (<37 weeks’ gestation)
delivery should be assessed for need for intrapartum pro-
phylaxis to prevent perinatal GBS disease. An algorithm
for management of women with threatened preterm
delivery is provided (Figure 3). Other management
approaches, developed by individual physicians or insti-
tutions, may be appropriate (CIII).
• Culture techniques that maximize the likelihood of GBS
recovery are required for prenatal screening (Box 1). Col-
lection of specimens for culture may be conducted in the
outpatient clinic setting by either the patient, with
appropriate instruction, or health-care provider (BII). This
involves swabbing the lower vagina and rectum (i.e.,
through the anal sphincter). Because lower vaginal as
opposed to cervical cultures are recommended, cultures
should not be collected by speculum examination. Speci-
mens should be placed in a nonnutritive transport
medium (e.g., Amies or Stuart’s without charcoal). Speci-
men labels should clearly identify that specimens are for
group B streptococcal culture. If susceptibility testing is
ordered for penicillin-allergic women (Box 2), specimen
labels should also identify the patient as penicillin allergic
and should specify that if GBS is isolated, it should be
tested for susceptibility to clindamycin and erythromy-
cin. Specimens should be inoculated into a selective broth
medium (examples of appropriate commercially available
media include Trans-Vag Broth supplemented with 5%
defibrinated sheep blood or LIM broth), incubated over-
night, and subcultured onto solid blood agar medium
(AII). Methods of testing prenatal isolates from penicillin-
allergic women for susceptibility to clindamycin and eryth-
romycin are outlined (Box 1). Laboratories should report
culture results (positive and negative) and susceptibility
testing results to the anticipated site of delivery (when
known) and to the health-care provider who ordered the test.
• Health-care providers should inform women of their GBS
screening test result and the recommended interventions.
In the absence of GBS urinary tract infection, antimicro-
bial agents should not be used before the intrapartum
period to treat GBS colonization. Such treatment is not
effective in eliminating carriage or preventing neonatal
disease and may cause adverse consequences (DI).
• GBS-colonized women who have a planned cesarean
delivery performed before rupture of membranes and
onset of labor are at low risk for having an infant with
early-onset GBS disease. These women should not rou-
tinely receive intrapartum chemoprophylaxis for perina-
tal GBS disease prevention (CII).
• For intrapartum chemoprophylaxis, the following regimen
is recommended for women without penicillin
allergy (Box 2): penicillin G, 5 million units intravenously
initial dose, then 2.5 million units intravenously every
4 hours until delivery (AII). Because of its narrow spec-
trum of activity, penicillin is the preferred agent. An
alternative regimen is ampicillin, 2 g intravenously initial
dose, then 1 g intravenously every 4 hours until delivery (AI).
• Intrapartum chemoprophylaxis for penicillin-allergic
women takes into account increasing resistance to
clindamycin and erythromycin among GBS isolates (Box 2).
During prenatal care, history of penicillin allergy should
be assessed to determine whether a patient is at high risk
for anaphylaxis, i.e., has a history of immediate hyper-
sensitivity reactions to penicillin (e.g., anaphylaxis,
angioedema, or urticaria) or history of asthma or other
conditions that would make anaphylaxis more dangerous
(89). Women who are not at high risk for anaphylaxis
should be given cefazolin, 2 g intravenously initial dose,
then 1 g intravenously every 8 hours until delivery (BIII).
For women at high risk for anaphylaxis, clindamycin and
erythromycin susceptibility testing, if available, should be
performed on isolates obtained during GBS prenatal
carriage screening. Women with clindamycin- and
erythromycin-susceptible isolates should be given either
clindamycin, 900 mg intravenously every 8 hours until
delivery; OR erythromycin, 500 mg intravenously every
6 hours until delivery. If susceptibility testing is not pos-
sible, susceptibility results are not known, or isolates are
resistant to erythromycin or clindamycin, the following
regimen can be used for women with immediate penicillin
hypersensitivity: vancomycin, 1 g intravenously every 12
hours until delivery (CIII).
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• Routine use of antimicrobial prophylaxis for newborns
whose mothers received intrapartum chemoprophylaxis
for GBS infection is not recommended. However, thera-
peutic use of these agents is appropriate for infants with
clinically suspected sepsis. An updated algorithm for man-
agement of infants born to mothers who received intra-
partum chemoprophylaxis for GBS infection is provided
(Figure 4). This revised algorithm is not an exclusive
approach to management; variation that incorporates
individual circumstances or institutional preferences may
be appropriate (CIII).
• Local and state public health agencies, in conjunction with
appropriate groups of hospitals, are encouraged to estab-
lish surveillance for early-onset GBS disease and to take
other steps to promote perinatal GBS disease prevention
and education to reduce the incidence of early-onset GBS
disease in their states. Efforts to monitor the emergence
of perinatal infections caused by other organisms are also
encouraged.
Before full implementation of this strategy can be expected
in all health-care settings, all members of the health-care team
will need to improve protocols for isolation and reporting of
GBS culture results, to improve information management to
ensure communication of screening results, and to educate
medical and nursing staff responsible for prenatal and intra-
partum care. Within institutions, such efforts may take sev-
eral months.
Even with ideal implementation, cases of early-onset GBS
disease will continue to occur. Tools to help promote preven-
tion and educate parents of infants with early-onset GBS
disease are available at http://www.cdc.gov/groupbstrep.
Additional tools available to assist with prevention implementa-
tion are available at http://www.acog.org, http://sales.acog.com,
http://www.aap.org and http://www.health.state.mn.us/divs/
dpc/ades/invbact/strepb.htm Multiple copies of educational
materials published by CDC are available at the Public Health
Foundation, 1220 L St., NW Suite 350, Washington, DC
20005, telephone 877-252-1200, or online at http://
www.phf.org.
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